Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
During a congressional hearing, neurologists warned that rare disease patients are dying while therapies linger in FDA review. The FDA recently rejected the SCA drug troriluzole, demanding more statistical certainty despite trial data showing over 50% fall‑risk reduction. Congress has granted flexibility to use real‑world evidence for rare diseases, yet the agency has not fully applied it. The decision threatens expanded‑access programs and highlights the tension between rigorous standards and urgent patient needs.
The only sustainable path to development of longevity therapeutics is to get the potential longevity drug approved for a disease, then go for indication expansion and study it in the context of aging at different doses and regimens. To be...
🔎 Chemical biology tools reveal which microbes are truly working behind the scenes 🔗 https://t.co/oFvPY4Uz95 🌐 #INPST #Biotech #CRBIOTECH https://t.co/tGA5P30yM1
Clinical trials have long relied on site‑based recruitment, leaving under‑ and misdiagnosed patients underrepresented. Recent studies show digital outreach can identify symptomatic individuals who never enter traditional healthcare pathways, dramatically expanding the eligible pool. Digital campaigns have cut cost per...
Consumer biotech will ultimately be bigger than consumer tech. What’s more valuable to people than health and wellness?
How do you break psychedelic molecules into parts, like cars in a chop shop, and build new ones? A look into non-psychedelic psychedelic medicine by Clayton Dalton, an ER doc and Ferriss-UC Berkeley Psychedelic Journalism Fellow @ucbsoj & @SciPsychedelics https://t.co/b7R4aTNdyf
Researchers have isolated and described a new planctomycete, Anatilimnocola aquadivae sp. nov., from deep subsurface percolate samples. Comprehensive phenotypic, electron‑microscopic, and genomic analyses place it within the Pirellulaceae family but as a distinct lineage. The genome encodes anaerobic respiration, aromatic‑compound...
We’ve trained a multimodal AI model to turn routine pathology slides into spatial proteomics, with the potential to reduce time and cost while expanding access to cancer care. https://t.co/OCptXdsUm1
1/9 Every bulk RNA-seq experiment I run goes through the same 7 checks before I trust the results. I've been burned enough times to know: if you skip QC, you will find out the hard way. Usually during a meeting with...
A recent study published in a leading gynecologic journal reveals that aberrant mRNA splice variants are a driving force behind the uncontrolled proliferation of endometriotic cells. Researchers identified a set of up‑regulated transcripts that activate the PI3K/AKT pathway, boosting lesion...
The Enemy isn't Big Pharma. It's the FDA and Regulators who won't allow you to test experimental therapies on yourself (or your dog). Even if it's life or death.
Single-dose rapamycin increases brain glucose metabolism but reduces synaptic density in Long-Evans rats [One week after intraperitoneal administration of rapamycin (8 mg/kg) 👨⚕️] https://t.co/6JhcZYS01h https://t.co/wruacgIvFM
Transcutaneous carbon dioxide (tcCO₂) monitoring is emerging as a viable alternative to arterial blood gases and end‑tidal CO₂ in neonatal and pediatric intensive care. Recent Pediatric Research data show a strong correlation between tcCO₂ readings and PaCO₂ in stable patients,...
The man engineering smarter, healthier babies before they're born: Jonathan Anomaly. This philosopher-turned-biotech founder says the future of your child's health starts at the embryo. Here are 9 things you need to know about embryo selection: https://t.co/XVQF5le4bE
Insulin-like peptide has antagonistic pleiotropic effects on male combat traits and survival traits in an armed beetle https://t.co/7Re0I2vcDW
Australian tech enthusiast Paul Conyngham used ChatGPT and AlphaFold to design a personalized mRNA vaccine for his dog Rose, whose tumor was genetically sequenced at UNSW. The AI‑assisted workflow identified mutations and suggested therapeutic targets, enabling a custom vaccine administered...
Researchers at Houston Methodist identified the ALS‑linked protein TDP43 as a regulator of DNA mismatch repair genes. Dysregulated TDP43—whether under‑ or over‑expressed—triggers abnormal repair activity that destabilizes the genome. Analysis of large cancer datasets revealed that tumors with high TDP43...
Japan has become the first country to grant conditional approval for two regenerative medicines that use induced pluripotent stem cells—AMCHEPRY for Parkinson’s disease and RiHEART for severe heart failure. The Parkinson’s therapy implants dopamine‑producing neurons into the brain, while the...
Isotonic and minimally invasive optical clearing media for live cell imaging ex vivo and in vivo "Here we develop minimally invasive optical clearing media for fluorescence imaging of live mammalian tissues.... SeeDB-Live minimally affects neuronal electrophysiological properties and sensory responses in...
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ. This post is a comprehensive recap of the past week in BioTech and gathers the best related posts written by some of the smartest & brightest 𝕏 Bio...
Penn State researchers have engineered a new class of granular aerogel scaffolds (GAS) that allow precise control of pore architecture using protein‑based microparticles. The tunable, oxygen‑rich material demonstrated superior cell infiltration and rapid vascularization in both laboratory assays and mouse...
Paul's story developing a cancer vaccine for Rosie inspired me. I'm going to build something so that EVERYONE can do the same thing. My dog Lady died of hemagiosarcoma and I wish I'd been able to save her too ETA - hopefully a...
In this episode, host Rizim Tom chats with Chris Bradley of MatterBio about the science of longevity, focusing on how genomic damage drives the hallmarks of aging. Bradley explains that while cells constantly renew, DNA damage from internal sources like...
These micro-cages are designed to hold and manipulate tiny cell clusters in miniaturized lab-on-a-chip devices. https://spectrum.ieee.org/lab-on-a-chip-grippers?share_id=9241061
Comprehensive molecular profiling of two stage IV NSCLC patients revealed distinct driver alterations—an EGFR exon 19 deletion in one and an EML4‑ALK fusion in the other—prompting personalized first‑line therapy with osimertinib and alectinib respectively. Both patients experienced rapid symptomatic improvement and enhanced...
A phase‑3 BMJ trial reported that adding camrelizumab to standard chemoradiotherapy improved 36‑month progression‑free, distant‑metastasis‑free and locoregional‑recurrence‑free survival in high‑risk nasopharyngeal carcinoma. The protocol combined two concurrent cycles with 17 adjuvant cycles, yet only 61.9% of patients completed the full...
Zydus Lifesciences has received NMPA approval for its oral anaemia drug Desidustat, targeting renal anaemia in adult chronic kidney disease patients who are not on dialysis. The therapy, a hypoxia‑inducible factor‑prolyl hydroxylase inhibitor, demonstrated efficacy and safety in Chinese Phase III...
The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...
AI: Short-Term Cliffs (0-3 years remaining): Drugs like sacubitril/valsartan, dapagliflozin, pembrolizumab, ocrelizumab, daratumumab, and apixaban face imminent generic/biosimilar pressure Mid-Term Protection (4-7 years): Risankizumab and dupilumab have solid runway, supported by ongoing label expansions. Long-Term (8+ years): Tirzepatide's robust patents position it...
YolTech Therapeutics announced FDA approval of its IND for YOLT-202, an in vivo adenine base‑editing therapy targeting Alpha‑1 Antitrypsin Deficiency. The clearance permits an open‑label, single‑dose Phase 2/3 expansion study across the U.S. and other regions. In the ongoing first‑in‑human trial,...
Overexpression of FoxO3a in the dentate gyrus alleviates CUS-induced anxiety- and depression-like behaviors and cognitive impairment https://t.co/p2t18NRkew
Cambridge chemists have unveiled a light‑driven “anti‑Friedel‑Crafts” reaction that forms carbon‑carbon bonds using only LED illumination at ambient temperature. The metal‑free method allows precise, late‑stage modifications of complex drug molecules, cutting months of multistep synthesis. Tested on a broad set...
A new multicenter study links dysregulated immune checkpoint pathways, especially PD‑1/PD‑L1 and CTLA‑4, to heightened severity in pediatric bronchiolitis. Researchers measured checkpoint molecule expression in airway samples from 312 infants and found that higher PD‑1 levels correlated with increased IL‑6,...
Epigenetic Clocks, Resilience, and Multi-Omics Ageing: A Review and the EpiAge-R Conceptual Framework The hierarchical architecture of the EpiAge-R framework... https://t.co/YpwDdLI7wo https://t.co/Uid3kNzDHr
Pretzel Therapeutics presented preclinical data for its investigational small‑molecule PX578 at the 2026 MDA Clinical and Scientific Conference. The drug is designed to activate the mitochondrial DNA polymerase gamma (POLG) and restore mitochondrial DNA levels in patients with mitochondrial DNA...
The FDA released draft Q&A guidance that clarifies how drug sponsors can qualify for three‑year non‑patent exclusivity by conducting a “new clinical investigation.” It defines a new study as a human, non‑bioavailability trial whose results have not been previously relied...
Friedreich ataxia (FA) received its first FDA‑approved therapy in 2023 when omaveloxolone, marketed as Skyclarys, earned accelerated approval. Biogen’s $7.3 billion acquisition of Reata Pharmaceuticals secured the drug and highlighted the market’s appetite for rare‑disease assets. Skyclarys works by activating the...
The study introduces a quantum‑annealing algorithm that predicts effective drug combinations by casting the problem as a quadratic unconstrained binary optimisation (QUBO). It leverages the network‑medicine concept of disease modules and the “Complementary Exposure” principle, which seeks drugs that hit...
A real‑time PCR assay for detecting Mycoplasma agalactiae in sheep bulk‑tank milk was developed and validated, showing high specificity and sensitivity. The test was deployed across more than 900 dairy sheep farms in Sardinia, revealing widespread but generally low‑level prevalence...
University of Florida researchers have achieved the first successful in‑vitro fertilization of a horse egg using frozen‑thawed sperm. The study showed that frozen‑thawed stallion sperm, after undergoing stress‑induced capacitation, fertilized the oocyte more effectively than fresh or chilled sperm. This...
A completely novel axis of epigenetic aging. N6-methyldeoxyadenosine (N6medA), i.e. NOT the usual 5 methyl cytosine, increases linearly with age in human prefrontal cortex (r=0.95). Genome-wide profiling reveals age-associated ADENINE methylation changes reminiscent of classic CpG based epigenetic clocks. Abdur...
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/L7r9caCcGN
The study introduces an operator‑based framework to assess pathway identifiability when metabolite coverage is incomplete. It aligns condition‑specific pathway graphs using a Johnson‑Lindenstrauss stabilized fused Gromov‑Wasserstein (JL‑FGW) operator and quantifies ambiguity via a composite functional that blends transport entropy, alignment...
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/W3vwHRTzhE
The FDA on March 10 expanded leucovorin’s label to cover a very rare genetic folate‑transport disorder, not autism. Earlier, Commissioner Marty Makary suggested the drug could help “hundreds of thousands of kids” with autism, creating expectations of a broad approval. FactCheck.org...
Alright, Alice 24-0001 petunia bits co-culturing with Agribacterium strain Gv3101 carrying a PcUBI4::RUBY::THSP construct. Testing out this ubiquitin promoter for stable transformation to avoid silencing. These will bake at 30°C until Monday and then transfered to selection. 🤞 https://t.co/SO1EKELMgU
Dompe, a privately owned biopharma, is advancing an intranasal nerve growth factor (NGF) therapy to treat non‑arteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden vision loss affecting roughly 6,000 U.S. patients annually. The approach leverages NGF’s neuroprotective...
An international research team has engineered a bacterial strain that boosts doxorubicin output by 180% compared with current industrial methods, overcoming three long‑standing bottlenecks—insufficient redox partners, drug‑binding “sponge” proteins, and suboptimal enzyme positioning. The findings, published in Nature Communications, detail...
During the COVID‑19 pandemic, vaccine makers pledged not to enforce mRNA‑related patents, but that restraint has ended, sparking a wave of litigation over lipid nanoparticle (LNP) and mRNA payload technologies. Major cases include Alnylam’s suits against Pfizer and BioNTech, Arbutus’s...
